Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis

BMC Medical Genetics

Nathorn Chaiyakunapruk³  Manupat Lohitnavy¹  Surasak Saokaew⁵  Elizabeth E Eickman⁴  Ratchadaporn Somkrua² 

[1] Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand;Center of Pharmaceutical Outcomes Research (CPOR), Naresuan University, Phitsanulok, Thailand;School of Pharmacy, University of Wisconsin, Madison, USA;Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha, Nebraska, USA;School of Pharmacy, University of Phayao, Phayao, Thailand

关键词: meta-analysis;    allopurinol;    toxic epidermal necrolysis;    Stevens-Johnson syndrome;    severe cutaneous reaction;    Human leukocyte antigen;   

Others  :  1177991
DOI  :  10.1186/1471-2350-12-118

 received in 2011-02-24, accepted in 2011-09-09,  发布年份 2011

【 摘 要 】

Background

Despite some studies suggesting a possible association between human leukocyte antigen, HLA-B*5801 and allopurinol induced Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), the evidence of association and its magnitude remain inconclusive. This study aims to systematically review and meta-analyze the association between HLA-B*5801 allele and allopurinol-induced SJS/TEN.

Methods

A comprehensive search was performed in databases including MEDLINE, Pre-MEDLINE, Cochrane Library, EMBASE, International Pharmaceutical Abstracts (IPA), CINAHL, PsychInfo, the WHO International, Clinical Trial Registry, and ClinicalTrial.gov from their inceptions to June 2011. Only studies investigating association between HLA-B*5801 with allopurinol-induced SJS/TEN were included. All studies were extracted by two independent authors. The primary analysis was the carrier frequency of HLA-B*5801 comparison between allopurinol-induced SJS/TEN cases and each comparative group. The pooled odds ratios were calculated using a random effect model.

Results

A total of 4 studies with 55 SJS/TEN cases and 678 matched-controls (allopurinol-tolerant control) was identified, while 5 studies with 69 SJS/TEN cases and 3378 population-controls (general population) were found. SJS/TEN cases were found to be significantly associated with HLA-B*5801 allele in both groups of studies with matched-control (OR 96.60, 95%CI 24.49-381.00, p < 0.001) and population-control (OR 79.28, 95%CI 41.51-151.35, p < 0.001). Subgroup analysis for Asian and Non-Asian population yielded similar findings.

Conclusion

We found a strong and significant association between HLA-B*5801 and allopurinol-induced SJS/TEN. Therefore, HLA-B*5801 allele screening may be considered in patients who will be treated with allopurinol.

【 授权许可】

   
2011 Somkrua et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Chan H, Stern R, Arndt K, Langlois J, Jick S, Jick H, Walker A: The incidence of erythema multiforme, sevens-johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990, 126(1):43-47.
• [2]Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N Engl J Med 1994, 331(19):1272-1285.
• [3]Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, Hollander N, Bruppacher R, Schopf E: Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996, 49(7):769-773.
• [4]Mockenhaupt M, Norgauer J: Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int 2002, 14:143-150.
• [5]Gerull R, Nelle M, Schaible T: Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review. Crit Care Med 2011, 39(6):1521-1532.
• [6]Roujeau JC: Clinical heterogeneity of drug hypersensitivity. Toxicology 2005, 209(2):123-129.
• [7]Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A: Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008, 128(1):35-44.
• [8]Melsom R: Familial hypersensitivity to allopurinol with subsequent desensitization. Rheumatology (Oxford) 1999, 38(12):1301.
• [9]Chung WH, Hung SI, Chen YT: Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007, 7:317-323.
• [10]Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005, 102(11):4134-4139.
• [11]Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, et al.: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008, 9(11):1617-1622.
• [12]Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, et al.: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008, 18(2):99-107.
• [13]Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, et al.: Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009, 19(9):704-709.
• [14]Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, Park HW, Chang YS, Jang IJ, Cho SH, et al.: Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011, 21(5):303-307.
• [15]Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, Park HW, Chang YS, Cho SH, Min KU, et al.: HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011, 0:1-6.
• [16]Roujeau JC: The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994, 102(6):28S-30S.
• [17]Bastuji-Garin S, Rzany B, Stern R: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erytherma multiforme. Arch Dermatol 1993, 129(1):92-96.
• [18]French LE: Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006, 55(1):9-16.
• [19]Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp] webcite (Accessed June 1, 2011)
• [20]Tanaka H, Akaza T, Juji T: Report of the Japanese Central Bone Marrow Data Center. Clin Transpl 1996, 139-144.
• [21]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
• [22]Higgins J, Thompson S: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
• [23]Begg C, Berlin J: Publication bias and dissemination of clinical research. J Natl Cancer Inst 1989, 81(2):107-115.
• [24]Egger M, Smith G: Bias in location and selection of studies. BMJ 1998, 316(7124):61-66.
• [25]Hanioka T, Ojima M, Tanaka K, Matsuo K, Sato F, Tanaka H: Causal assessment of smoking and tooth loss: A systematic review of observational studies. BMC Public Health 2011, 11(1):221. BioMed Central Full Text
• [26]Loke Y, Price D, Herxheimer A, the Cochrane Adverse Effects Methods G: Systematic reviews of adverse effects: framework for a structured approach. BMC Medical Research Methodology 2007, 7(1):32. BioMed Central Full Text
• [27]Smith L, Foxcroft D: The effect of alcohol advertising, marketing and portrayal on drinking behaviour in young people: systematic review of prospective cohort studies. BMC Public Health 2009, 9(1):51. BioMed Central Full Text
• [28]Wahabi H, Alzeidan R, Bawazeer G, Alansari L, Esmaeil S: Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis. BMC Pregnancy and Childbirth 2010, 10(1):63. BioMed Central Full Text
• [29]Munafo MR, Flint J: Meta-analysis of genetic association studies. Trends Genet 2004, 20(9):439-444.
• [30]Klein J, Sato A: The HLA system, first of two parts. N Engl J Med 2000, 343(10):702-709.
• [31]Halevy S, Mockenhaupt M, Fagot JP, Bavinck JNB, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC: Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008, 58:25-32.
• [32]Arellano F, Sacristan JA: Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993, 27(3):337-343.
• [33]Markel A: Allopurinol-induced DRESS syndrome. Isr Med Assoc J 2005, 7:656-660.
• [34]Bugelski PJ: Genetic aspects of immune-mediated adverse drug effects. Nat Rev Drug Discov 2005, 4:59-69.
• [35]Stevanovic S: Structural basis of immunogenicity. Transpl Immunol 2002, 10:133-136.
• [36]Ou YC, Conolly RB, Thomas RS, Gustafson DL, Long ME, Dobrev ID, Chubb LS, Xu Y, Lapidot SA, Andersen ME, et al.: Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay. Toxicol Sci 2003, 73(2):301-314.
• [37]Conolly RB, Andersen ME: Hepatic foci in rats after diethylnitrosamine initiation and 2,3,7,8-tetrachlorodibenzo-p-dioxin promotion: evaluation of a quantitative two-cell model and of CYP 1A1/1A2 as a dosimeter. Toxicol Appl Pharmacol 1997, 146(2):281-293.
• [38]Lu Y, Lohitnavy M, Reddy M, Lohitnavy O, Eickman E, Ashley A, Gerjevic L, Xu Y, Conolly RB, Yang RS: Quantitative analysis of liver GST-P foci promoted by a chemical mixture of hexachlorobenzene and PCB 126: implication of size-dependent cellular growth kinetics. Arch Toxicol 2008, 82(2):103-116.
• [39]Ou YC, Conolly RB, Thomas RS, Xu Y, Andersen ME, Chubb LS, Pitot HC, Yang RS: A clonal growth model: time-course simulations of liver foci growth following penta- or hexachlorobenzene treatment in a medium-term bioassay. Cancer Res 2001, 61(5):1879-1889.
• [40]Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3(5):541-547.
• [41]Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270(5238):985-988.
• [42]Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006, 7(6):813-818.
• [43]Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006, 16(4):297-306.
• [44]Ikeda H, Takahashi Y, Yamazaki E, Fujiwara T, Kaniwa N, Saito Y, Aihara M, Kashiwagi M, Muramatsu M: HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 2010, 51(2):297-300.
• [45]Middleton D, Menchaca L, Rood H, Komerofsky R: New allele frequency database: http://www.allelefrequencies.net webcite. Tissue Antigens 2003, 61(5):403-407.
• [46]Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, et al.: HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010, 51(12):2461-2465.
• [47]Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA: Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011, 127(3 Suppl):S60-66.